Key Takeaway: Aclaris Therapeutics, Inc. announced its participation in two healthcare conferences in February 2026. The events will feature live and archived webcasts accessible on their website for at least 30 days. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Price reaction · baseline $3.47 (2026-02-03 close) · hit pre-market · clean, no other ACRS news in the window
day 0 close · peak
+2%
Market Sentiment Analysis
POSITIVE FACTORS
Aclaris is actively participating in healthcare conferences.
The company is focused on developing novel treatments for immuno-inflammatory diseases.
Webcasts of the events will be available for public access.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis
Full Press Release Details
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026.
A live and archived webcast of both events will be accessible on theEvents pageofhttps://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris onLinkedIn.